Head to Head Contrast: TherapeuticsMD (TXMD) vs. Assembly Biosciences (ASMB)
TherapeuticsMD (NASDAQ: TXMD) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitabiliy, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.
Institutional & Insider Ownership
68.9% of Assembly Biosciences shares are held by institutional investors. 19.6% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares TherapeuticsMD and Assembly Biosciences’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|TherapeuticsMD||$18.41 million||58.26||-$90.40 million||N/A||N/A|
|Assembly Biosciences||$684,369.00||548.23||-$47.84 million||($2.74)||-7.89|
Assembly Biosciences has higher revenue, but lower earnings than TherapeuticsMD.
This table compares TherapeuticsMD and Assembly Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and price targets for TherapeuticsMD and Assembly Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TherapeuticsMD currently has a consensus price target of $17.17, indicating a potential upside of 226.36%. Assembly Biosciences has a consensus price target of $35.00, indicating a potential upside of 61.81%. Given TherapeuticsMD’s higher possible upside, equities analysts clearly believe TherapeuticsMD is more favorable than Assembly Biosciences.
Assembly Biosciences beats TherapeuticsMD on 7 of the 10 factors compared between the two stocks.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.